|
ANDA Filers Fret: Stability Testing Tweaks Will Delay Approvals
The FDA’s plan to require more stability data for ANDAs is likely to slow approvals unless the agency flexes a little, generic-drug makers say.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives